Moreover, syngeneic mouse models showed that the murine surrogate of C5252 has superior anti-tumor activity compared to the unarmed backbone virus, with enhanced immune activation. Taken together, our findings support C5252 as a promising therapeutic option for glioblastoma treatment, positioning it as a highly promising candidate for clinical translation.

8 months ago

Journal

CASP3 (Caspase 3) • CASP7 (Caspase 7) • CNTFR (Ciliary Neurotrophic Factor Receptor)

MVR-C5252

9ms

PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)

P1, N=51, Not yet recruiting, Duke University | Initiation date: Feb 2024 --> May 2024

9 months ago

Trial initiation date

MVR-C5252

1year

PuMP: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (clinicaltrials.gov)

P1, N=51, Not yet recruiting, Duke University

1 year ago

New P1 trial

MVR-C5252

2years

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. (PubMed, Front Oncol)

Efficacy studies demonstrated that combination with T7011 and CAR-T or CAR-T cells showed significant synergistic anti-tumor responses in several solid tumor models. These studies indicated that the new generation of oHSV T7011 can be a promising combinational therapy with CD19 or BCMA-specific CAR T cells for the treatment of a broad range of solid tumors.

2 years ago

Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker

CD19 (CD19 Molecule)

CD19 expression

MVR-C5252